Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4WUU

Structure of ESK1 in complex with HLA-A*0201/WT1

Summary for 4WUU
Entry DOI10.2210/pdb4wuu/pdb
DescriptorHLA class I histocompatibility antigen, A-2 alpha chain, Beta-2-microglobulin, ARG-MET-PHE-PRO-ASN-ALA-PRO-TYR-LEU, ... (5 entities in total)
Functional Keywordsantibody, mhc 1, wt1, hla-a*0201, immune system
Biological sourceHomo sapiens (Human)
More
Cellular locationMembrane; Single-pass type I membrane protein: P01892
Secreted : P61769
Total number of polymer chains5
Total formula weight93942.25
Authors
Ataie, N.J.,Ng, H.L. (deposition date: 2014-11-03, release date: 2015-12-30, Last modification date: 2024-10-23)
Primary citationAtaie, N.,Xiang, J.,Cheng, N.,Brea, E.J.,Lu, W.,Scheinberg, D.A.,Liu, C.,Ng, H.L.
Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.
J.Mol.Biol., 428:194-205, 2016
Cited by
PubMed Abstract: Antibody therapies currently target only extracellular antigens. A strategy to recognize intracellular antigens is to target peptides presented by immune HLA receptors. ESK1 is a human, T-cell receptor (TCR)-mimic antibody that binds with subnanomolar affinity to the RMF peptide from the intracellular Wilms tumor oncoprotein WT1 in complex with HLA-A*02:01. ESK1 is therapeutically effective in mouse models of WT1(+) human cancers. TCR-based therapies have been presumed to be restricted to one HLA subtype. The mechanism for the specificity and high affinity of ESK1 is unknown. We show in a crystal structure that ESK1 Fab binds to RMF/HLA-A*02:01 in a mode different from that of TCRs. From the structure, we predict and then experimentally confirm high-affinity binding with multiple other HLA-A*02 subtypes, broadening the potential patient pool for ESK1 therapy. Using the crystal structure, we also predict potential off-target binding that we experimentally confirm. Our results demonstrate how protein structure information can contribute to personalized immunotherapy.
PubMed: 26688548
DOI: 10.1016/j.jmb.2015.12.002
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.047 Å)
Structure validation

231029

건을2025-02-05부터공개중

PDB statisticsPDBj update infoContact PDBjnumon